Literature DB >> 19762359

Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

M C van der Goes1, J W G Jacobs, M Boers, T Andrews, M A M Blom-Bakkers, F Buttgereit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, L Guillevin, M Holland, J R Kirwan, J Rovensky, K G Saag, G Severijns, S Webber, R Westhovens, J W J Bijlsma.   

Abstract

OBJECTIVE: To explore perspectives among patients and rheumatologists on glucocorticoid (GC) therapy and European League Against Rheumatism (EULAR) recommendations on the management of systemic GC therapy in order to enhance implementation of the recommendations.
METHODS: Rheumatologists (from eight countries) and patients (from five countries) acquainted with GCs participated in separate meetings, during which positive and negative aspects of GC therapy were discussed and possible adverse events (AEs) were ranked for importance; in addition participants were asked to evaluate the published EULAR recommendations. The reports from these meetings and themes related to implementation of the recommendations were discussed during an international forum of the experts who had formulated the recommendations and patient participants.
RESULTS: In all, 140 patients (78% women; mean age 53 years; 61% patients with rheumatoid arthritis) and 110 rheumatologists (mean work experience 15 years) participated in the meetings. Osteoporosis, diabetes and cardiovascular diseases were ranked among the five most worrisome AEs by patients and rheumatologists. In both groups, there was agreement with most of the recommendations; the recommendations on GC information cards and GC use during pregnancy scored lowest. Ideas to improve implementation of the recommendations and a research agenda were generated.
CONCLUSION: The patient and rheumatologist views on GCs corresponded to a large extent, reflected by concerns in both groups about osteoporosis, diabetes and cardiovascular diseases. Specific problems with the EULAR recommendations were identified and addressed to improve their implementation. This exercise shows that patient and rheumatologist perspectives should be included early in the process of formulating recommendations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762359     DOI: 10.1136/ard.2009.114579

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  Topical 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice.

Authors:  Ana Tiganescu; Melanie Hupe; Yoshikazu Uchida; Theadora Mauro; Peter M Elias; Walter M Holleran
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

Review 2.  [Long-term glucocorticoid therapy : Is there a safe dosage?].

Authors:  C Strehl; F Buttgereit
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

Review 3.  Views on glucocorticoid therapy in rheumatology: the age of convergence.

Authors:  Frank Buttgereit
Journal:  Nat Rev Rheumatol       Date:  2020-02-19       Impact factor: 20.543

4.  Rheumatoid arthritis: Glucocorticoid therapy and body composition.

Authors:  Frank Buttgereit; Gerd R Burmester
Journal:  Nat Rev Rheumatol       Date:  2016-07-07       Impact factor: 20.543

Review 5.  [Diagnostics and treatment of polymyalgia rheumatica].

Authors:  C Dejaco; E L Matteson; F Buttgereit
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

6.  Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.

Authors:  Katinka Albrecht; Dörte Huscher; Frank Buttgereit; Martin Aringer; Guido Hoese; Wolfgang Ochs; Katja Thiele; Angela Zink
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

7.  [Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].

Authors:  D Freier; C Strehl; F Buttgereit
Journal:  Hautarzt       Date:  2020-02       Impact factor: 0.751

8.  Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study.

Authors:  Zachary S Wallace; Tyler Harkness; Xiaoqing Fu; John H Stone; Hyon K Choi; Rochelle P Walensky
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

Review 9.  [Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].

Authors:  D Freier; C Strehl; F Buttgereit
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

Review 10.  Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis.

Authors:  Jos N Hoes; Johannes W G Jacobs; Frank Buttgereit; Johannes W J Bijlsma
Journal:  Nat Rev Rheumatol       Date:  2010-12       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.